We viewed that BTZ could be a potential drug for neoplastic bone defects, as BTZ was found to inhibit osteoclast differentiation through ubiquitin-mediated SMURF and NF-κB pathway, thereby reducing OVX-induced osteoporosis in mice [28, 51, 52]. This evidence concerns the gene NFKB1 and osteoporosis.